Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Nov 13.
doi: 10.1111/add.70233. Online ahead of print.

Changes in clinical features and severity in patients presenting to European emergency departments with acute cannabis toxicity over the 10-year period from 2013 to 2022

Òscar Miró  1   2 , Miguel Galicia  1 , Paul I Dargan  3   4 , David M Wood  3   4 , Alison M Dines  3 , Fridtjof Heyerdahl  5   6 , Knut Erik Hovda  6   7 , Isabelle Giraudon  8 , Christopher Yates  9 , Matthias Liechti  10 , Odd Martin Vallersnes  11   12 , Florian Eyer  13 , Guillermo Burillo-Putze  14 ; *the Euro‐DEN Plus Research Group
Collaborators, Affiliations

Changes in clinical features and severity in patients presenting to European emergency departments with acute cannabis toxicity over the 10-year period from 2013 to 2022

Òscar Miró et al. Addiction. .

Abstract

Background and aims: In recent years, the potency of natural cannabis products (herb and resin) has increased with a higher delta- 9-tetrahydrocannabinol (Δ9-THC) content, but there are limited data on trends on clinical presentation and severity of toxicity in cannabis users consulting the emergency department (ED) for acute intoxication. This study aimed to analyse the evolution over time of clinical findings and severity of presentations in a large series of patients presenting to European EDs with acute toxicity after lone cannabis use.

Design: Secondary analysis of data included in the Euro-DEN Registry from 1 October 2013 to 31 December 2022.

Setting: 40 EDs in 25 European countries.

Participants/cases: ED presentations reporting lone cannabis use. Presentations reporting concomitant use of, or having positive toxicological tests for, ethanol or other drugs were excluded. 3839 ED presentations reporting lone cannabis use were analysed (median age 25 years, interquartile range= 20-33; 71% male).

Measurements: Temporal trends of 14 pre-defined clinical signs/symptoms and 4 markers of severity, which included the need for ambulance transfer to the ED, hospitalisation, intensive care unit admission (ICU) and death.

Findings: The most frequent clinical features were anxiety (35%), agitation (22%), decreased alertness (drowsiness or coma, 21%) and vomiting (20%), while seizures, arrythmias and hyperthermia were observed in <3% of cases. Statistically significant changes over time were only found in the frequency of hypotension [adjusted odds ratio (OR) = 1.239 per every subsequent year, 95% confidence interval (CI) = 1.107-1.386], hypertensive crisis (OR = 1.168, 95% CI = 1.070-1.274) and palpitations (OR = 0.922, 95% CI = 0.883-0.962). Nonlinear analyses detected statistically significant mid-period increases for anxiety, agitation and arrhythmias that subsided by the end of the study, and showed increases in chest pain and decreases in seizures that became statistically significant in the latter half of the period. Regarding episode severity, 76% of cases were brought to the ED by ambulance, 13% required hospitalisation, 1% were admitted to the ICU and 0.1% died. No statistically significant changes were observed over time in either the linear or the nonlinear models.

Conclusion: Very few changes in the clinical features of patients presenting to European emergency departments with lone acute cannabis toxicity were identified over 2013 to 2022, suggesting that despite the increase in potency of cannabis in Europe over this period, the severity of acute intoxication has remained unchanged.

Keywords: cannabis; emergency department; hashish; marihuana; severity; temporal trends.

PubMed Disclaimer

References

REFERENCES

    1. ElSohly MA, Mehmedic Z, Foster S, Gon C, Chandra S, Church JC. Changes in cannabis potency over last two decades (1995‐2014). Analysis of current data in the United States. Biol Psychiatry. 2016;79:613–619.
    1. Freeman TP, Groshkova T, Cunningham A, Sedefov R, Griffiths P, Lynksey MT. Increasing potency and price of cannabis in Europe, 2006‐2016. Addiction. 2019;114:1015–1023.
    1. Dujourdy L, Besacier F. A study of cannabis potency in France over a 25 years period (1992‐2016). Forensic Sci Int. 2017;272:72–80. https://doi.org/10.1016/j.forsciint.2017.01.007
    1. Petrilli K, Hines L, Adams S, Morgan CJ, Curran HV, Freeman TP. High potency cannabis use, mental health symptoms and cannabis dependence: triangulating the evidence. Addict Behav. 2023;144:107740. https://doi.org/10.1016/j.addbeh.2023.107740
    1. Manthey J, Freeman TP, Kilian C, López‐Pelayo H, Rehm J. Public health monitoring of cannabis use in Europe: Prevalence of use, cannabis potency, and treatment rates. Lancet Reg Health Eur. 2021;10:100227.

LinkOut - more resources